Endocannabinoid Blockade for Improving Glycemic Control and Lipids in Patients with Type 2 Diabetes Mellitus

American Journal of Medicine

Volumn 120, Issue 2 SUPPL., 2007, Pages

  Hollander, Priscilla ^a  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

Author keywords

Diabetes; Lipids; Metabolic syndrome; Rimonabant; RIO Diabetes

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; METFORMIN; PLACEBO; RIMONABANT; SULFONYLUREA;

ANXIETY DISORDER; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIABETIC PATIENT; DIARRHEA; DIET RESTRICTION; DIET THERAPY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; LOW CALORY DIET; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PARESTHESIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCREENING; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RISK FACTORS; TREATMENT OUTCOME;

EID: 33846815271     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2006.11.014     Document Type: Article

References (45)

1. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
2. Bray G.A. Medical consequences of obesity. J Clin Endocrinol Metab 89 (2004) 2583-2589
3. Carey D.G., Jenkins A.B., Campbell L.V., Freund J., and Chisholm D.J. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 45 (1996) 633-638
4. Carr M.C., and Brunzell J.D. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab 89 (2004) 2601-2607
5. Steiner G. Treating lipid abnormalities in patients with type 2 diabetes mellitus. Am J Cardiol 88 (2001) 37N-40N
6. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
7. Alexander C.M., Landsman P.B., Teutsch S.M., Haffner S.M., and Third National Health and Nutrition Examination Survey (NHANES III) and the National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52 (2003) 1210-1214
8. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H., and Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003) 383-393
9. Stamler J., Stamler R., Neaton J.D., et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA 282 (1999) 2012-2018
10. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
11. Huxley R., Barzi F., and Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 332 (2006) 73-78
12. Howard B.V., Best L.G., Galloway J.M., et al. Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care 29 (2006) 391-397
13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
14. Pasternak R.C. Report of the Adult Treatment Panel III: the 2001 National Cholesterol Education Program guidelines on the detection, evaluation and treatment of elevated cholesterol in adults. Cardiol Clin 21 (2003) 393-398
15. Scheen A.J. Current management strategies for coexisting diabetes mellitus and obesity. Drugs 63 (2003) 1165-1184
16. Scheen A.J., Finer N., Hollander P., Jensen M.D., Van Gaal L.F., and RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368 (2006) 1660-1672
17. Wing R.R., Marcus M.D., Epstein L.H., and Salata R. Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care 10 (1987) 563-566
18. Pi-Sunyer F.X. Weight and non-insulin-dependent diabetes mellitus. Am J Clin Nutr 63 (1996) 426S-429S
19. Williamson D.F., Thompson T.J., Thun M., Flanders D., Pamuk E., and Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 23 (2000) 1499-1504
20. Guare J.C., Wing R.R., and Grant A. Comparison of obese NIDDM and nondiabetic women: short- and long-term weight loss. Obes Res 3 (1995) 329-335
21. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
22. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
23. Despres J.P., Golay A., and Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 (2005) 2121-2134
24. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., and Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
25. Di M.V., Bifulco M., and De P.L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3 (2004) 771-784
26. Cota D., Marsicano G., Tschop M., et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112 (2003) 423-431
27. Horvath T.L. Endocannabinoids and the regulation of body fat: the smoke is clearing. J Clin Invest 112 (2003) 323-326
28. Di M.V., Goparaju S.K., Wang L., et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410 (2001) 822-825
29. Di Marzo V., Bifulco M., and De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3 (2004) 771-784
30. Pagotto U., and Pasquali R. Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. Lancet 365 (2005) 1363-1364
31. Matsuzawa Y., Funahashi T., Kihara S., and Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24 (2004) 29-33
32. Jbilo O., Ravinet-Trillou C., Arnone M., et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 19 (2005) 1567-1569
33. 1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63 (2003) 908-914
34. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J., and Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. RIO-North America: a randomized controlled trial. JAMA 295 (2006) 761-775
35. Zigmond A.S., and Snaith R.P. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67 (1983) 361-370
36. Kirk J.K., Huber K.R., and Clinch C.R. Attainment of goals from national guidelines among persons with type 2 diabetes: a cohort study in an academic family medicine setting. N C Med J 66 (2005) 415-419
37. Prevost G., Phan T.M., Mounier-Vehier C., and Fontaine P. Control of cardiovascular risk factors in patients with type 2 diabetes and hypertension in a French national study (Phenomen). Diabetes Metab 31 (2005) 479-485
38. Eliasson B., Cederholm J., Nilsson P., and Gudbjornsdottir S. The gap between guidelines and reality: type 2 diabetes in a National Diabetes Register 1996-2003. Diabet Med 22 (2005) 1420-1426
39. Wadden T.A., and Foster G.D. Behavioral treatment of obesity. Med Clin North Am 84 (2000) 441-461 vii
40. Blackburn G. Effect of degree of weight loss on health benefits. Obes Res 3 suppl 2 (1995) 211s-216s
41. NIH Technology Assessment Conference Panel. Methods for voluntary weight loss and control. Consensus Development Conference, 30 March to 1 April 1992. Ann Intern Med 119 (1993) 764-770
42. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
43. Osei-Hyiaman D., DePetrillo M., Pacher P., et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115 (2005) 1298-1305
44. Liu Y.L., Connoley I.P., Wilson C.A., and Stock M.J. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) 29 (2005) 183-187
45. Chandran M., Phillips S.A., Ciaraldi T., and Henry R.R. Adiponectin: more than just another fat cell hormone?. Diabetes Care 26 (2003) 2442-2450